Cytotoxic dose-response relationships in small cell lung cancer

Cancer Treatment Reviews

Volumn 23, Issue 4, 1997, Pages 191-207

  Thomas, A L ^a   Woll, P J ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE PAIN; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOXICITY; FEASIBILITY STUDY; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MATHEMATICAL MODEL; META ANALYSIS; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030692626     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90011-6     Document Type: Article

References (78)

1. Frei, E. & Cannellos, G. P. (1980) Dose: A critical factor in cancer chemotherapy. Am. J. Medicine 69: 585-591.
2. Spiro, S. G., Souhami, R. L., Geddes, D. M. et al. (1989) Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br. J. Cancer 59: 578-583.
3. Giaccone, G., Dalesio, O., McVie, G. et al. For the EORTC (1993) Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomised trial. J. Clin. Oncol. 11; 7:1230-1240.
4. Stahel, R. A., Ginsberg, R., Havemann, K. et al. (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5: 119-126.
5. Souhami, R. L., Bradbury, I., Geddes, D. M., Spiro, S. G., Harper, P. G. & Tobias, J. S. (1985) Prognostic significance of laboratory parameters measured at diagnosis in small cell cancer of the lung. Cancer Res. 45: 2878-2882.
6. Cerny, T., Blair, V., Anderson, H., Bramwell, V. & Thatcher, N. (1978) Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int. J. Cancer 39: 146-149.
7. Rawson, N. S. B. & Peto, J. (1990) An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Co-ordinating Committee on Cancer Research. Br. J. Cancer 61: 597-604.
8. Hryniuk, W. & Bush, H. (1984) The importance of dose intensity in the chemotherapy of metastatic breast cancer. J. Clin. Oncol 2: 1281-1288.
9. Hryniuk, W. & Levine, M. N. (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol. 4: 8; 1162-1170.
10. Epelbaum, R., Haim, N,. Ben-Shahar, M,. Ron, Y. & Cohen, Y. (1988) Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr. J. Med. Sci. 24: 533.
11. Wampler, G. L. & Fryer, J. G. (1992) Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples. Cancer Chemother. Pharmacol. 30: 99-206.
12. Gurney, H., Dodwell, D,. Thatcher, N. & Tattershall, M. H. N. (1993) Escalating drug delivery in cancer therapy; A review of concepts and practice - Part 1. Annals of Oncol. 4: 23.
13. Gurney, H., Dodwell, D., Thatcher, N. & Tattersall, M. H. N. (1993) Escalating drug delivery in cancer chemotherapy; A review of concepts and practice - Part 2. Annals of Oncol. 4: 103-115.
14. Klasa, R., Murray, N. & Coldman, A. (1991) Dose intensity meta analysis of chemotherapy regimens in small cell carcinoma of the lung. J. Clin. Oncol. 9: 499-508.
15. Sirzea, F., Westberg, R., Lewensohn, R. & Billing, B. (1994) Dose intensity of the CAVE regimen in small cell lung cancer correlates to response rate. Lung Cancer 11: 393.
16. Pettengell, R. & Crowther, D. (1994) Haemopoietic growth factors and dose intensity in high and intermediate grade non-Hodgkin's lymphoma. Annals Oncol. 5 (Suppl. 2): 133-141.
17. Thigpen, J. T. (1997) Dose-intensity in ovarian carcinoma: hold, enough? J. Clin. Oncol. 15: 4; 1291-1293.
18. Sheehan, R. G., Balaban, E. P. & Frenkel, E. P. (1993) The impact of dose intensity of standard chemotherapy regimens in extensive stage small cell lung cancer. Am. J. Clin. Oncol. 16; 3: 250-255.
19. Cohen, M. H., Creaven, P.J. & Fossieck, B. E. (1972) Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat. Rep. 61: 349-354.
20. Johnson, D. H., Einhorn, L. H., Birch, R. et al. (1987) A randomised comparison of high dose versus conventional dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: A phase III trial of the Southeastern Cancer study group. J. Clin. Oncol. 5: 1731-1738.
21. Ihde, D. C., Mulshine, J. L., Kramer, B. S. et al. (1994) Prospective randomised comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensivestage small cell lung cancer. J. Clin. Oncol. 12; 10: 2022-2034.
22. de Vathaire, F., Arrigada, R., de The, H. et al. (1993) Dose intensity of initial chemotherapy may have an impact on survival in limited small cell lung cancer. Lung Cancer 8: 310-308.
23. Arriagada, R., Le Chevalier, T., Pignon, J. et al. (1993) Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med. 329: 1848-1852.
24. Klimo, P., Connors, J. M. (1985) MACOP-B chemotherapy in the treatment of large cell lymphoma. Ann. Intern. Med. 102: 596-602.
25. Fischer, R., Gaynor, E., Dahlberg, H. et al. (1993) A phase III comparison of CHOP v m-BACOD v PromACE-CytaBOM v MACOP-B in patients with intermediate or high grade non Hodgkin's lymphoma. Preliminary results of SWOG-8516 the National high priority lymphoma study. N. Engl. J. Med. 328: 1002-1006.
26. Miles, D. W., Earl, H. M., Souhami, R. L. et al. (1991) Intensive weekly chemotherapy for good-prognosis patients with small cell lung cancer. J. Clin. Oncol. 2: 280-285.
27. Taylor, C. W., Crowley, J., Williamson, S. K. et al. (1990) Treatment of small cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group Pilot Study. J. Clin. Oncol. 8: 1811-1817.
28. Murray, N., Shah, A., Osba, D. et al. (1991) Intensive weekly chemotherapy for treatment of extensive stage small cell lung cancer. J. Clin. Oncol. 9: 1632-1638.
29. Goldie, J. H., Coldman, A. J. & Gudauskas, G. A. (1982) Rationale for the use of alternating non-cross resistance chemotherapy. Cancer Treat. Rep. 63: 439-449.
30. Evans, W. K., Feld, R., Murray, N. et al. (1987) Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. Ann. Inter. Med. 107: 451-458.
31. Fukuoka, M., Furure, K., Saijo, N. et al. (1991) Randomised trial of cyclophosphamide, doxorubicin and vincristine versus etoposide plus cisplatin versus alternation of these regimens in small cell lung cancer. J. Natl Cancer Inst. 83: 855-861.
32. Roth, B. J., Johnson, D. H., Einhorn, L. H. et al. (1992) Randomised study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern cancer study group. J. Clin. Oncol. 10: 282-291.
33. Kristensen, K. A., Jensen, P. B., Poulsen, H. S. & Hansen, H. H. (1996) Small cell lung cancer: biological and therapeutic aspects. Critical Rev. Oncol./Haematol. 22: 27-60.
34. Souhami, R. L., Rudd, R., Ruiz de Elvira, M-C. et al. (1994) Randomised trial comparing weekly versus 3-weekly chemotherapy in small cell lung cancer: A Cancer Research Campaign Trial. J. Clin. Oncol. 12; 9: 1806-1813.
35. Gower, N. H., Rudd, R. M., Ruiz de Elvira, M-C. et al. (1995) Assessment of quality of life using a daily diary card in a randomised trial of chemotherapy in small cell lung cancer. Ann. Oncol. 6: 575-580.
36. Miles, D. W., Fogarty, O., Ash, C. M. et al. (1994) Received dose intensity: A randomised trial of weekly chemotherapy with and without Granulocyte colony stimulating factor in small cell lung cancer. J. Clin. Oncol. 12; 1: 77-82.
37. Goodman, G. E., Crowley, J. J., Blasko, J. C. et al. (1990) Treatment of limited stage small cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin and cyclophosphamide, versus concurrent etoposide, vincristine, doxorubicin and cyclophosphamide and chest radiotherapy: a South-western Oncology Group Study. J. Clin. Oncol. 8: 39-47.
38. Bronchud, M. H., Scarffe, J. H., Thatcher, N. et al. (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br. J. Cancer 56: 809-813.
39. Crawford, J., Ozer, H., Stoller, R. et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Eng. J. Med. 325: 164-170.
40. Trillet-Lenoir, V., Green, J. A., Manegold, C. et al. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer 29A: 319-324.
41. Trillet-Lenoir, V., Green, J. A., Manegold, C. et al. (1995) Recombinant Granulocyte colony-stimulating factor in the treatment of small cell lung cancer: A long term follow-up. Eur. J. Cancer 31A; 12: 2115-2116.
42. Bunn, P. A., Crowley, J., Kelly, K. et al. (1995) Chemoradiotherapy with or without GM-CSF in the treatment of Limited stage small cell lung cancer: A prospective phase III randomised study of the Southwest Oncology Group. J. Clin. Oncol. 13; 7: 1632-1641.
43. Nakamura, H., Sayami, P. & Hayata, Y. (1992) Analysis of G-CSF-producing lung cancer cell lines and non-growth-stimulatory effects of rhG-CSF on lung cancer cells in vitro and in vivo. Lung Cancer 8: 141-152.
44. Twentyman, P. R., Wright, K. A. (1991) Failure of GM-CSF to influence the growth of small cell and non-small cell lung cancer cell lines in vitro. Eur. J. Cancer 27: 6-8.
45. Vellenga, E., Biesma, B., Meyer, C. et al (1991) The effects of five hematopoietic growth factors on human small cell lung carcinoma cell lines: interleukin 3 enhances the proliferation in one of eleven cell lines. Cancer Res. 51: 73-76.
46. de Campos, E., Radford, J., Steward, W. et al. (1995) Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small cell lung cancer. J. Clin. Oncol. 13; 7: 1623-1631.
47. Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S. & Vadhan-Raj, S. (1997) Impact of therapy with erythropoietin on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice. J. Clin. Oncol. 15: 1218-1234.
48. Ardizzoni, A., Venturini, M., Crino, L. et al. (1992) High dose intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor in the treatment of small cell lung cancer. Eur. J. Cancer 29A: 5: 687-692.
49. Spiro, S. G., Souhami, R. L., Geddes, D. M. et al. (1989) Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br. J. Cancer 59: 578-583.
50. Medical Research Council Lung Cancer Working Party. (1992) A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine in small cell lung cancer: Survival and prognostic factors. Br. J. Cancer 68: 1150-1156.
51. Wolf, M., Hans, K., Drings, P. et al. (1996) Treatment intensification with GM-CSF in patients with non-metastatic small cell lung cancer (NMSCLC). Results of a multicenter trial including 330 patients. Proc. Am. Soc. Clin. Oncol. 15: 716.
52. Thatcher, N., Clark, P. I., Smith, D. B. et al. (1995) Increasing and planned dose intensity of Doxorubicin, Cyclophosphamide, and Etoposide (ACE) by adding Recombinant Human Methionyl Granulocyte colony-stimulating factor (G-CSF; Filgrastim) in the treatment of small cell lung cancer. Clinical Oncology 7: 293-299.
53. Thatcher, N., Anderson, H., Bleehan, N. H. et al. On behalf of the Medical Research Council Lung Cancer Working Party. (1995) The feasibility of using Glycosylated recombinant Granulocyte Colony-Stimulating Factor (G-CSF) to increase the planned dose intensity of Doxorubicin, Cyclophosphamide and Etoposide (ACE) in the treatment of small cell lung cancer. Eur. J. Cancer 31 A; 2: 152-156.
54. Gridelli, C., Perrone, F., D'aprile, M. et al. (1995) Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF in extensive stage small cell lung cancer. Eur. J. Cancer 31A: 2424-2426.
55. Trillet-Lenoir, V., Soler, P., Arpin, D. et al. (1996) The limits of dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer. Lung Cancer 14: 331-341.
56. Woll, P. J., Hodgetts, J., Lomax, L., Bildet, F., Cour-Chabernaud, V. & Thatcher, N. (1995) Can cytotoxic dose intensity be increased by using granulocyte colony-stimulating factor? A randomised controlled trial of Lenograstim in small cell lung cancer. J. Clin. Oncol. 13: 3: 652-659.
57. Steward, W., von Pawel, J., Gatzeimer, U., Woll, P. J. & Frisch, J. (1994) Dose-intensification of vincristine, ifosfamide, carboplatin and etoposide (VICE) ± rhGM-CSF in small cell lung cancer. Lung cancer 11; S1: 375.
58. Eguchi, K., Etou, H., Miyachi, S. et al. (1994) A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Eur. J. Cancer 30A: 188-94.
59. Katakami, N., Takada, M., Negoro, S. et al. (1996) Dose escalation study of carboplatin with fixed dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung cancer. Cancer 77, 1: 63-70.
60. Paccagnella, A., Favaretto, A., Riccardi, A. et al. (1993) Granulocyte-Macrophage Colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Cancer 72; 3: 697-706.
61. Spitzer, G., Spencer, V. & Dunphy, F. R. (1992) High dose chemotherapy with autologous bone marrow support for lung cancer. In: High-dose Cancer Therapy. Baltimore: Williams & Wilkins.
62. Smith, I. E., Evans, B. D., Harland, S. J. et al. (1985) High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother. Pharmacol. 14: 120-124.
63. Humblet, Y., Symann, M., Bosly, A. et al. (1987) Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomised study. J. Clin. Oncol. 5: 1443-1454.
64. Elias, A. D., Ayash, L., Frei III, E. et al.. (1993) Intensive combined modality therapy for limited-stage small cell lung cancer. JNCI 85; 7: 559-566.
65. Farha, P., Spitzer, G., Valdivieso, M. et al. (1983) High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung cancer. Cancer 52: 1351-1355.
66. Souhami, R. L., Hajichristou, H. T., Miles, D. W. et al. (1989) Intensive chemotherapy with autologous bone marrow transplantation for small cell lung cancer. Cancer Chemother. Pharmacol. 24: 3210-3325.
67. Brugger, W., Bross, K., Frisch, J. et al. (1992) Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 79; 5: 1193-1200.
68. Brugger, W., Frommhold, H., Pressler, K., Mertelsmann, R. & Kanz, L (1995) Use of high dose etoposide, ifosfamide, carboplatin, epirubicin and peripheral blood progenitor cell transplantation in limited stage small cell lung cancer. Sem. Oncol. 22: 1, suppl. 2: 3-8.
69. Brugger, W., Bross, K. J. & Glatt, M. et al (1994) Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumours. Blood 83: 636-640.
70. Tepler, I., Cannistra, S. A., Frei, E. et al. (1992) Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J. Clin. Oncol. 11: 1583-1591.
71. Shea, T. C., Mason, J. R., Storniolo, A. M., Newton, B., Breslin, M., Mullen, M. et al. (1992) Sequential cycles of high-dose carboplatin administered with granulocyte-macrophage colony-stimulating factor and repeated infusion of autologous peripheral-blood progenitor cell: A novel and effective method for delivering multiple courses of dose-intensive therapy. J. Clin. Oncol. 10: 464-473.
72. Pettengell, R., Woll, P. J., Thatcher, N., Dexter, M., Testa, Nydia. (1995) Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of haematopoetic progenitors in whole blood. J. Clin. Oncol. 13: 1: 148-156.
73. Pettengell, R., Woll, P. J., O'Connor, D. A. et al. (1994) Viability of hematopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transpl. 14: 703-709.
74. Woll, P. J., Lee, S. M., Lomax, L. et al. (1996) Randomised phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoeitic progenitors in whole blood in small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 15: 957.
75. Pignon, J. P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L. et al. (1992) A meta-analysis of thoracic radiotherapy for small cell lung cancer. N. Eng. J. Med. 327: 1618-1624.
76. Thatcher, N., Lind, M., Stout, R., Payne, C., Carroll, K. B., Campbell, C. et al. (1989) Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for "limited" stage small cell carcinoma of the bronchus. Br. J. Cancer 60: 98-101.
77. Prendiville, J., Lorigan, P., Hicks, F., Leahy, B., Stout, R., Burt, P. & Thatcher, N. (1994) Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. Eur. J. Cancer 30A; 14: 2085-2090.
78. Woll, P. J., Thatcher, N. (1995) Bronchus. In: Treatment of Cancer. Third edition., London: Chapman and Hall Medical.